U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H13N5O5S2
Molecular Weight 395.414
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFDINIR, (E)-

SMILES

[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N\O)\C3=CSC(N)=N3)C(O)=O

InChI

InChIKey=RTXOFQZKPXMALH-RWFJUVPESA-N
InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7+/t8-,12-/m1/s1

HIDE SMILES / InChI

Molecular Formula C14H13N5O5S2
Molecular Weight 395.414
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

Description

Cefdinir is an extended-spectrum, semisynthetic cephalosporin, for oral administration. As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, β-lactamase enzymes. Cefdinir is indicated for the treatment of: Community-Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis, Acute Maxillary Sinusitis, Pharyngitis/Tonsillitis and Uncomplicated Skin and Skin Structure Infections. Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain. Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox® TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. As with other β-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CEFDINIR
Curative
CEFDINIR
Curative
CEFDINIR
Curative
CEFDINIR
Curative
CEFDINIR
Curative
CEFDINIR

Cmax

ValueDoseCo-administeredAnalytePopulation
1 μg/mL
200 mg single, oral
CEFDINIR plasma
Homo sapiens
1.55 μg/mL
300 mg single, oral
CEFDINIR plasma
Homo sapiens
2.15 μg/mL
400 mg single, oral
CEFDINIR plasma
Homo sapiens
2.35 μg/mL
600 mg single, oral
CEFDINIR plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
4.08 μg × h/mL
200 mg single, oral
CEFDINIR plasma
Homo sapiens
6.53 μg × h/mL
300 mg single, oral
CEFDINIR plasma
Homo sapiens
8.83 μg × h/mL
400 mg single, oral
CEFDINIR plasma
Homo sapiens
9.84 μg × h/mL
600 mg single, oral
CEFDINIR plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
1.43 h
200 mg single, oral
CEFDINIR plasma
Homo sapiens
1.46 h
300 mg single, oral
CEFDINIR plasma
Homo sapiens
1.43 h
400 mg single, oral
CEFDINIR plasma
Homo sapiens
1.5 h
600 mg single, oral
CEFDINIR plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
39%
200 mg single, oral
CEFDINIR plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer










Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
The total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as BID dosing. Usual Adult Dose for Pneumonia: 300 mg orally every 12 hours for 10 to 14 days Acute exacerbations of chronic bronchitis: 300 mg orally every 12 hours for 5 to 10 days or 600 mg orally every 24 hours for 10 days Acute maxillary sinusitis: 300 mg orally every 12 hours or 600 mg orally every 24 hours for 10 days
Route of Administration: Oral
In Vitro Use Guide
Cefdinir had a much higher MIC90 against genotypic penicillin-resistant Streptococcus pneumoniae (gPRSP) than cefditoren and cefcapene (8 mg/L cefdinir vs. 1 mg/L cefditoren and cefcapene).
Substance Class Chemical
Record UNII
61G2M33IGF
Record Status Validated (UNII)
Record Version